Role of antibiotic use, plasma citrulline and blood microbiome in advanced non-small cell lung cancer patients treated with nivolumab

Table 2 Multivariate analyses (Cox model) on PFS and OS

	Progression-free survival		Overall survival
	HR (IC95%)	p-value	HR (IC95%)	p-value
EUA	1.6 (0.6–2.2)	0.645	2.2 (1.1–4.8)	0.038
PS 2	2.1 (1.1–4.1)	0.023	1.8 (0.7–4.4)	0.198
Hg rate (continuous)	0.8 (0.0–0.9)	0.005	0.8 (0.6–1.1)	0.174
Alb rate < 30 g/dl	1.1 (0.5–2.3)	0.908	0.5 (0.2–1.5)	0.216
Kras mutation	0.7 (0.4–1.2)	0.181	0.4 (0.0–0.9)	0.020
PDL1 ≥ 1%	1.6 (0.6–4.2)	0.295	3.0 (0.9–10.8)	0.085
Citrulline < 20 μM	3.8 (1.4–99.9)	0.008	2.4 (0.6–10)	0.222
Presence of Gemmatimonadaceae	2.9 (0.9–9.2)	0.073	16.4 (3.9–68.5)	< 0.001

HR hazard ratio, EUA early use of antibiotics, PS Performance status, Hg hemoglobin, Alb albumin